Merck KGaA may have struggled getting new drug products to market, but its $17 billion buyout of Sigma-Aldrich will allow it to help others, as well as itself, in that endeavor.
After a failed attempt to revive its late-stage program for Stimuvax, Merck KGaA is once again throwing in the towel on the cancer vaccine. The German company's biopharma division will cut its two monotherapy studies in the wake of another recent trial failure in Japan, it said late last week.
Merck KGaA emphasized the importance of China as a market when it announced last year it would build a new plant there, and again last month when it announced it was getting ready to start construction on the facility. And this week, just in case anyone had missed it, the drugmaker said construction had begun on the plant which will make meds on China's essential drug list.
Back in 2012, researchers flagged some positive results for patient subgroups in a flunked trial of Merck KGaA's cancer vaccine. But now, the vaccine has hit another snag, failing to hit its primary endpoint--as well as three secondary endpoints--in a Japanese trial, partner Oncothyreon said Monday in an SEC filing.
Germany's Merck KGaA is expanding its headquarters and manufacturing operations in Darmstadt, Germany. On Monday, Merck said it is investing about €27 million (about $36.3 million) to build two power plants that it says will provide more power more efficiently, while reducing carbon dioxide emissions in the area.
Merck KGaA will start construction next month on a plant to make diabetes drugs in China, a market it says is key to its future. The market is so important that the executive board of the German drugmaker held an event there to reiterate that point to Chinese officials.
Personalized medicine is the latest trend in companion diagnostics, and companies are teaming up to develop comprehensive tests based on a patient's biologic characteristics. Roche's Ventana Medical Systems sees potential in the field, and recently inked a deal with Germany's Merck KGaA to develop a companion diagnostic test for different cancer indications.
Having already bought the land on which Merck KGaA's salt plant in Lehrte, Germany, sits, salt maker Schüssler Novachem has now bought the production and laboratory equipment from the German drugmaker.
The FDA gave de novo approval to Menlo Park-based Auxogyn's Eeva System, a fertility-enhancing diagnostic test currently available in Europe and Canada.
The market for multiple sclerosis drugs is not an easy one, especially now that Biogen Idec's soaring Tecfidera has arrived on the scene. But MS drugmakers Novartis and Merck KGaA are doing what they can to keep their edges, rolling out a pair of digital solutions to help patients manage the disease.